SecBot SecBot
PRESS-RELEASE ·Filed May 1, 2026

AXSM

Axsome Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should watch for initial prescription data and payer coverage decisions over the next 1-2 quarters, which will determine the commercial ramp.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$206.53
T+0 close · May 1, 2026 · via day close
Latest settled
+13.40%
T+60 · $234.20
Vs SPY
+10.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $206.53entry
  2. T+1 · 7mo ago +8.31%α +8.65% · $223.70
  3. T+5 · 6mo ago +6.63%α +4.28% · $220.22
  4. T+20 · 6mo ago +11.48%α +6.20% · $230.25
  5. T+60 · 4mo ago +13.40%α +10.33% · $234.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's disease dementia, a major label expansion for an already-approved MDD drug. This addresses a large, underserved patient population (up to 76% of >7M Alzheimer's patients) with no approved treatment, creating a significant commercial opportunity.

Key Facts

  • FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment targeting NMDA and sigma-1 receptors.
  • Alzheimer's disease affects >7 million people in the U.S., with agitation reported in up to 76% of patients.
  • AUVELITY was initially approved for MDD in 2022 and is protected by a robust patent estate extending to at least 2043.
  • The approval addresses a condition with no currently approved treatment, representing a significant unmet medical need.

Financial Impact

Significant revenue expansion potential from a large, untreated patient population; no specific financial figures provided in the release.

revenue

Risk Factors

  • Commercial execution risk: adoption by physicians and patients may be slower than expected.
  • Payer coverage and reimbursement challenges could limit market access.
  • Safety concerns (Boxed Warning for suicidal thoughts) may dampen prescribing in elderly Alzheimer's patients.
  • Competition from off-label antipsychotics or future entrants.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285840

Track record

26 reports on AXSM

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026